Epirium Bio
Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule 15-PGDH inhibitors that restore PGE-2 signaling. Its lead candidate MF-300 is in Phase 2b for sarcopenia, with additional programs in Becker muscular dystrophy and inflammatory bowel disease.
- Company typePrivate
- Founded2008
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Epirium Bio does
Epirium Bio is a clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 and previously operating as Cardero Therapeutics, Inc. The company has built an IP-protected platform of orally bioavailable small molecules that inhibit the 15-PGDH enzyme, a "gerozyme" that degrades prostaglandin E2 (PGE-2) and rises with age. By restoring PGE-2 signaling, the platform aims to re-establish tissue homeostasis, resolve aberrant inflammation, stimulate regeneration, and reduce fibrosis across neuromuscular and inflammatory diseases.
The company's lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently advancing into a Phase 2b trial in sarcopenia (age-related muscle weakness), supported by a completed Phase 1 trial in 88 participants that demonstrated target engagement, tolerability, and safety in healthy volunteers and older adults. The pipeline additionally includes EPM-01, an oral compound targeting mitochondrial dysfunction in Becker muscular dystrophy that has completed Phase 1, and MF-1305, an oral 15-PGDH inhibitor in IND-enabling studies for inflammatory bowel disease. Preclinical efficacy has been generated across spinal muscular atrophy and idiopathic pulmonary fibrosis, signaling platform breadth.
Epirium Bio operates a pre-revenue pharmaceutical development model: it generates no current product revenue and will monetize via traditional pharmaceutical commercialization (wholesalers, specialty pharmacies, hospital networks) following FDA approval of MF-300 and pipeline assets. The company is backed by $85 million in Series A financing from ARCH Venture Partners, Longitude Capital, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, Longevity Fund, and Horizons Ventures. Recent FDA milestones include IND clearance for MF-300 (December 2024) and a positive Type C meeting outcome (January 2026), positioning the Phase 2b trial initiation for mid-2026.
Epirium Bio firmographics
Firmographics- Name
- Epirium Bio
- Legal name
- Epirium Bio
- Website
- https://epirium.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Epirium Bio is a clinical-stage biopharmaceutical company developing orally bioavailable small molecule 15-PGDH inhibitors that restore PGE-2 signaling. Its lead candidate MF-300 is in Phase 2b for sarcopenia, with additional programs in Becker muscular dystrophy and inflammatory bowel disease.
- Ownership category
- akta.pro rank
Epirium Bio industry classification
Industry- Product category
- Biopharmaceutical Drug Development
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
Keywords
Where Epirium Bio is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Epirium Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing small molecule drugs for neuromuscular diseases (sarcopenia, Becker muscular dystrophy, SMA) and inflammatory/fibrotic diseases (IBD, IPF). Revenue will be generated upon FDA approval and commercialization of MF-300 and pipeline candidates.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Epirium Bio product offering
Product offeringCore offering
Epirium Bio develops an IP-protected platform of orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently in Phase 2b for sarcopenia, with additional pipeline candidates targeting Becker muscular dystrophy (EPM-01), inflammatory bowel disease (MF-1305), and other neuromuscular and fibrotic indications.
Product overview
Epirium Bio is a biopharmaceutical company with an IP-protected platform of orally bioavailable small molecules leveraging PGE-2 signaling to restore tissue homeostasis. The company's core product portfolio includes: MF-300 (Phase 2b for sarcopenia), a first-in-class oral 15-PGDH enzyme inhibitor; EPM-01 (completed Phase 1 for Becker muscular dystrophy); and MF-1305 (IND enabling for IBD). The platform has generated preclinical efficacy data across indications including spinal muscular atrophy (SMA), irritable bowel disease (IBD), and idiopathic pulmonary fibrosis (IPF).
Differentiator
Problem solved
Functional benefit
Products and services
- MF-300 First-in-class oral small molecule 15-PGDH enzyme inhibitor under development for the treatment of sarcopenia (age-related muscle weakness). Currently advancing through Phase 2b clinical trials with demonstrated target engagement, safety, and tolerability in Phase 1 trials involving 88 participants.
- EPM-01 Novel, oral, synthetic compound targeting mitochondrial dysfunction for the treatment of Becker muscular dystrophy, with demonstrated proof-of-concept in multiple preclinical and clinical studies.
- MF-1305 Oral 15-PGDH inhibitor in IND-enabling stage for inflammatory bowel disease, including ulcerative colitis and Crohn's disease.
Quantifiable outcome
- Phase 1 results demonstrated target engagement, good tolerability, and safety in healthy volunteers and older adults (88 participants)
- +2 more outcomes
Companies that use Epirium Bio
Customer profileSegments5 records
Ideal customer profiles2 records
Epirium Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Epirium Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor.
- Parent Project Muscular Dystrophy (PPMD)minorThe largest nonprofit organization in the United States focused on finding a cure for Duchenne muscular dystrophy. Partnered for patient resources and clinical trial support.
- Muscular Dystrophy Association (MDA)minorNonprofit health agency committed to transforming lives of people living with muscular dystrophy, ALS, and related neuromuscular diseases. Has committed more than $1 billion to research.
Scale indicators4 records
Recent moves9 records
Expansion highlights6 records
Epirium Bio competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Epirium Bio social profiles
Digital presenceEpirium Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Epirium Bio leadership team
Management profileNumber of profiles
Profiles6 records
Epirium Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Epirium Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Epirium Bio
What does Epirium Bio do?
Epirium Bio develops an IP-protected platform of orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis, resolve inflammation, and stimulate regeneration. Its lead candidate, MF-300, is a first-in-class oral 15-PGDH enzyme inhibitor currently in Phase 2b for sarcopenia, with additional pipeline candidates targeting Becker muscular dystrophy (EPM-01), inflammatory bowel disease (MF-1305), and other neuromuscular and fibrotic indications.
Is Epirium Bio a public or private company?
Epirium Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Epirium Bio founded?
Epirium Bio was founded in 2008. It employs 11 to 50 people.
Where is Epirium Bio based?
Epirium Bio is headquartered in San Diego, United States, in the North America region.
How does Epirium Bio make money?
One revenue line is on record: pharmaceutical Drug Development and Commercialization.
Does Epirium Bio have an API?
No public API is recorded for Epirium Bio.
What industry is Epirium Bio in?
Epirium Bio's product category is Biopharmaceutical Drug Development. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics). Its NAICS code is 541714 and its SIC code is 2836.